Cyclo Therapeutics (CYTH) Competitors $0.72 0.00 (0.00%) As of 03/26/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CYTH vs. IZTC, CRDL, OPTN, DBVT, TCRX, VIGL, ZURA, CLYM, IVVD, and SLSShould you be buying Cyclo Therapeutics stock or one of its competitors? The main competitors of Cyclo Therapeutics include Invizyne Technologies (IZTC), Cardiol Therapeutics (CRDL), OptiNose (OPTN), DBV Technologies (DBVT), TScan Therapeutics (TCRX), Vigil Neuroscience (VIGL), Zura Bio (ZURA), Climb Bio (CLYM), Invivyd (IVVD), and SELLAS Life Sciences Group (SLS). These companies are all part of the "pharmaceutical products" industry. Cyclo Therapeutics vs. Invizyne Technologies Cardiol Therapeutics OptiNose DBV Technologies TScan Therapeutics Vigil Neuroscience Zura Bio Climb Bio Invivyd SELLAS Life Sciences Group Invizyne Technologies (NASDAQ:IZTC) and Cyclo Therapeutics (NASDAQ:CYTH) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, community ranking, valuation, analyst recommendations, media sentiment, risk, earnings and profitability. Does the media refer more to IZTC or CYTH? In the previous week, Cyclo Therapeutics had 4 more articles in the media than Invizyne Technologies. MarketBeat recorded 4 mentions for Cyclo Therapeutics and 0 mentions for Invizyne Technologies. Cyclo Therapeutics' average media sentiment score of 0.72 beat Invizyne Technologies' score of 0.67 indicating that Cyclo Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Invizyne Technologies Positive Cyclo Therapeutics Positive Do insiders & institutionals have more ownership in IZTC or CYTH? 68.6% of Cyclo Therapeutics shares are held by institutional investors. 29.8% of Cyclo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has stronger valuation & earnings, IZTC or CYTH? Invizyne Technologies has higher earnings, but lower revenue than Cyclo Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInvizyne TechnologiesN/AN/AN/AN/AN/ACyclo Therapeutics$870.73K27.24-$20.06M-$0.90-0.80 Is IZTC or CYTH more profitable? Invizyne Technologies has a net margin of 0.00% compared to Cyclo Therapeutics' net margin of -2,847.19%. Company Net Margins Return on Equity Return on Assets Invizyne TechnologiesN/A N/A N/A Cyclo Therapeutics -2,847.19%N/A -307.16% Do analysts prefer IZTC or CYTH? Cyclo Therapeutics has a consensus target price of $0.95, suggesting a potential upside of 31.83%. Given Cyclo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cyclo Therapeutics is more favorable than Invizyne Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cyclo Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Does the MarketBeat Community believe in IZTC or CYTH? Cyclo Therapeutics received 10 more outperform votes than Invizyne Technologies when rated by MarketBeat users. CompanyUnderperformOutperformInvizyne TechnologiesN/AN/ACyclo TherapeuticsOutperform Votes1071.43% Underperform Votes428.57% SummaryCyclo Therapeutics beats Invizyne Technologies on 9 of the 11 factors compared between the two stocks. Remove Ads Get Cyclo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYTH vs. The Competition Export to ExcelMetricCyclo TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.72M$3.03B$5.63B$8.10BDividend YieldN/A1.54%4.56%4.02%P/E Ratio-0.8029.1624.5519.02Price / Sales27.24434.62383.6492.49Price / CashN/A168.6838.1634.64Price / Book3.433.976.954.34Net Income-$20.06M-$71.95M$3.20B$247.23M7 Day Performance5.97%-4.87%-2.42%-0.71%1 Month Performance-6.43%-9.62%2.96%-3.92%1 Year Performance-48.53%-25.93%11.14%1.61% Cyclo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYTHCyclo Therapeutics2.8894 of 5 stars$0.72flat$0.95+31.8%-50.2%$23.72M$870,725.00-0.809Upcoming EarningsShort Interest ↓News CoverageIZTCInvizyne TechnologiesN/A$14.81-1.9%N/AN/A$92.59MN/A0.00N/ANews CoverageCRDLCardiol Therapeutics2.7569 of 5 stars$1.12flat$8.40+650.0%-45.3%$92.52MN/A-2.8720OPTNOptiNose2.7052 of 5 stars$9.17+0.2%$9.00-1.9%-58.7%$92.25M$75.67M-2.18190Earnings ReportHigh Trading VolumeDBVTDBV Technologies3.2928 of 5 stars$4.46-10.6%$22.50+404.5%-47.8%$91.74M$15.73M-0.9980News CoverageTCRXTScan Therapeutics3.8354 of 5 stars$1.60-4.2%$9.33+483.3%-81.9%$90.55M$2.82M-1.51100Short Interest ↓VIGLVigil Neuroscience3.9654 of 5 stars$1.90+0.5%$16.25+755.3%-35.5%$88.68MN/A-0.9240Short Interest ↓ZURAZura Bio2.0506 of 5 stars$1.35-2.9%$15.80+1,070.4%-40.9%$88.15MN/A0.003Earnings ReportAnalyst ForecastNews CoverageCLYMClimb Bio3.0045 of 5 stars$1.32+1.5%$10.00+657.6%N/A$87.39MN/A-0.629Earnings ReportNews CoverageIVVDInvivyd3.6039 of 5 stars$0.72-1.9%$7.89+989.4%-83.2%$86.60M$25.38M-0.37100Earnings ReportAnalyst ForecastShort Interest ↓Gap DownSLSSELLAS Life Sciences Group0.4111 of 5 stars$1.23+2.5%N/A+11.3%$86.57M$1M-1.7810Earnings ReportPositive News Remove Ads Related Companies and Tools Related Companies IZTC Alternatives CRDL Alternatives OPTN Alternatives DBVT Alternatives TCRX Alternatives VIGL Alternatives ZURA Alternatives CLYM Alternatives IVVD Alternatives SLS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYTH) was last updated on 3/27/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
